• Users Online: 238
  • Print this page
  • Email this page
Year : 2022  |  Volume : 26  |  Issue : 2  |  Page : 92-95

Topical immunotherapy for alopecia areata: A successful diphenylcyclopropenone protocol

1 Department of Medicine, Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada
2 Department of Sciences, Faculty of Sciences, University of Alberta, Edmonton, Alberta, Canada

Correspondence Address:
Dr. Navdeep Dhaliwal
University of Alberta, 116 Street and 85 Avenue, Edmonton T6G 2R3, Alberta
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jdds.jdds_21_22

Rights and Permissions

Alopecia areata (AA) is an autoimmune disorder that involves the destruction of anagenic hair follicles, resulting in non-scarring patchy hair loss. The patient presented in the following case had not seen improvement by use of conventional treatments and was started on topical immunotherapy, diphenylcyclopropenone (DPCP). This agent is commonly left as a last resort due to its constant need for follow-up, clinician-required administration, and risk of adverse effects. The following case presents a titration schedule using DPCP, resulting in minimal adverse effects and dramatic improvement in hair regeneration.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded49    
    Comments [Add]    

Recommend this journal